Beta Bionics, Inc. (BBNX) vs Corvus Pharmaceuticals, Inc. (CRVS)
A side-by-side comparison of Beta Bionics, Inc. and Corvus Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BBNX
Beta Bionics, Inc.
$19.25HealthcareDelayed quote: Oct 6, 2026, 9:35 AM EDT
CRVS
Corvus Pharmaceuticals, Inc.
$10.61HealthcareDelayed quote: Oct 6, 2026, 9:34 AM EDT
Total return — BBNX vs CRVS
growth of $100 · dividends reinvested · last 2yBBNX -19.8% (-10.4%/yr)CRVS +111.4% (+45.4%/yr)CRVS compounded faster over this window
BBNX CRVS
BBNX vs CRVS: by the numbers
- •CRVS is the larger company ($892M vs $866M market cap).
- •Both run net losses; CRVS's is the smaller (0.00% vs -61.32% net margin).
Metrics side by side
Valuation
| Metric | BBNX | CRVS |
|---|---|---|
| P/S ratio | 7.28 | N/A |
| P/B ratio | 3.38 | 3.96 |
Profitability
| Metric | BBNX | CRVS |
|---|---|---|
| Gross margin | 58.31% | 0.00% |
| Operating margin | -69.75% | 0.00% |
| Net margin | -61.32% | 0.00% |
| ROE | -28.46% | -24.02% |
| ROIC | -31.17% | -25.25% |
Growth (annualized)
| Metric | BBNX | CRVS |
|---|---|---|
| Total return CAGR (5Y) | N/A | 17.88% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.